DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bosentan Use in Patients With Diabetic Nephropathy

Information source: Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 2 Diabetes

Intervention: bosentan (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Centre hospitalier de l'Université de Montréal (CHUM)

Official(s) and/or principal investigator(s):
Maryse Courteau, MD, Principal Investigator, Affiliation: CHUM

Summary

There is little doubt of the necessity for further improvement in the prevention and therapy of end-stage renal disease. Despite the success of ARB in treating diabetic nephropathy, not all patients obtain satisfactory control of blood pressure, albuminuria and decline in renal function. Experimental data have provided us with a rationale for the potential added benefits of ET receptor blockade to the AII inhibition in diabetic renal protection. Considering the nephroprotective effect of bosentan in diabetic rats, clinical studies are warranted to assess whether ET receptor antagonism has additive renoprotective effects on top of AII inhibition.

Clinical Details

Official title: Effect of Bosentan on Systemic and Renal Inflammatory Markers in Patients With Diabetic Nephropathy on Angiotensin II Receptor Blockers

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF

Secondary outcome: change from baseline to week 16 in renal functioning. The following renal function parameter will be measured: - 24h UAE;

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Men or women ≥ 18 years of age with a body weight of ≥ 40 kg;

- For female patients, only non-pregnant women who are surgically sterile,

postmenopausal or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of childbearing potential using intrauterine devices (IUDs);

- Patients diagnosed Type 2 diabetes with overt nephropathy (urinary albumin excretion

≥ 300mg/24h);

- Patients on current treatment with angiotensin II receptor blockers for ≥ 3 months;

- Patients stable for at least 3 months prior to screening (no change in medications

for diabetic nephropathy);

- Provide written informed consent;

Exclusion Criteria:

- Patients with a history of pulmonary chronic obstructive disease, cardiac failure or

coronary artery disease;

- Patients with documented cancers, acute infections or chronic inflammatory

diseases;

- Patients who are pregnant or breast-feeding;

- Patients with known hepatic disorders or AST and ∕or ALT upper than normal limit;

- Patients with hemoglobin or hematocrit that is ≥ 30% below the normal range (patients

with secondary polycythemia are permitted);

- Patients with systolic blood pressure < 110mm Hg;

- Patients with plasmatic albumin level < 30g/L;

- Patients with a documented creatinine clearance ≤ 60ml/min;

- Patients on anticoagulants or anti-inflammatory drugs, including cyclooxygenase

inhibitors, AINS, prednisone and immunosuppressive drugs, platelet aggregation inhibitors, except low dose aspirin, ACE inhibitors, antidiabetic agents (rosiglitazone, pioglitazone) and antioxidants (vitamin E)(except statins or low-dose aspirin ≤ 80mg/day);

- Patients on treatment or planned treatment with another investigational drug;

- Patients who are receiving an endothelin receptor antagonist, phosphodiesterase type

5 inhibitor, or with a prostanoid (excluding acute administration during a catheterization procedure to test vascular reactivity) within 2 months of inclusion;

- Patients who are receiving calcineurin-inhibitors (i. e., cyclosporine A and

tacrolimus), fluconazole, glibenclamide (glyburide) at inclusion or are expected to receive any of these drugs during the study;

- Patients with a known hypersensitivity to bosentan or any of the excipients;

Locations and Contacts

CHUM, Montreal, Quebec H2L 4M1, Canada
Additional Information

Starting date: January 2009
Last updated: June 14, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017